Llwytho...
Tyrosine kinase inhibitors induce mesenchymal stem cell–mediated resistance in BCR-ABL(+) acute lymphoblastic leukemia
Tyrosine kinase inhibitors (TKIs) are used as a frontline therapy for BCR-ABL(+) acute lymphoblastic leukemia (ALL). However, resistance to TKI therapy arises rapidly, and its underlying molecular mechanisms are poorly understood. In this study, we identified a novel cascade of events initiated by T...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Blood |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society of Hematology
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4424418/ https://ncbi.nlm.nih.gov/pubmed/25712988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-576421 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|